Our new cardiotoxicity assay, Cardio quickPredict, will be available in early 2018. The assay will indicate the cardiotoxicity potential of drug candidates and other lead compounds, based on changes in human induced pluripotent stem cell-derived cardiomyocyte (iPSC-CM) metabolism and viability.
The assay will provide an indication of cardiotoxicity, as well as whether the compound’s cardiotoxicity profile is consistent with functional or structural changes. In other words, Cardio quickPredict will combine a metabolism-based cardiotoxicity assay with a traditional electrophysiological assay in a single product.
Final Assay Design
In a recent study, we exposed iPSC-derived cardiomyocytes to 57 compounds and analyzed the spent media using UPLC-HRMS-based metabolomics. The training set consisted of 20 non-cardiotoxic compounds and 37 cardiotoxic compounds that elicit a broad range of outcomes including structural and functional cardiotoxicity. (For full details, view the poster.)
Read our Cardio quickPredict brochure for more information.
Cardioqp uses iCell® Cardiomyocytes2: Video of beating iCell® Cardiomyocytes courtesy of Cellular Dynamics International, a FUJIFILM company
Contact us if you’re interested in beta testing Cardio quickPredict. You can help us solidify the product and receive a discounted rate!